Acta Diabetologica, Journal Year: 2023, Volume and Issue: 61(2), P. 253 - 255
Published: Sept. 30, 2023
Language: Английский
Nature Reviews Endocrinology, Journal Year: 2024, Volume and Issue: 20(7), P. 426 - 440
Published: April 8, 2024
Language: Английский
Citations
27
Journal of Diabetes & Metabolic Disorders, Journal Year: 2025, Volume and Issue: 24(1)
Published: Feb. 1, 2025
Language: Английский
Citations
1
Journal of Pain Research, Journal Year: 2024, Volume and Issue: Volume 17, P. 4223 - 4237
Published: Dec. 1, 2024
Remote Patient Monitoring (RPM) stands as a pivotal advancement in patient-centered care, offering substantial improvements the diagnosis, management, and outcomes of chronic conditions. Through utilization advanced digital technologies, RPM facilitates real-time collection transmission critical health data, enabling clinicians to make prompt, informed decisions that enhance patient safety particularly within home environments. This narrative review synthesizes evidence from peer-reviewed studies evaluate transformative role RPM, its integration with Artificial Intelligence (AI), managing conditions such heart failure, diabetes, pain. By highlighting advancements disease-specific applications, underscores RPM's versatility ability empower patients through education, shared decision-making, adherence therapeutic regimens. The COVID-19 pandemic further emphasized importance ensuring healthcare continuity during systemic disruptions. AI has refined these capabilities, personalized, data analysis. While pain management serves focal area, also examines AI-enhanced applications cardiology diabetes. AI-driven systems, NXTSTIM EcoAI™, are highlighted for their potential revolutionize treatment approaches continuous monitoring, timely interventions, improved outcomes. progression basic wearable devices sophisticated, systems redefine delivery, reduce system burdens, quality life across multiple Looking forward, AI-integrated is expected refine disease strategies by more personalized effective treatments. broader implications, including applicability cardiology, showcase capacity deliver automated, data-driven thereby reducing burdens while enhancing life.
Language: Английский
Citations
7
Journal of Managed Care & Specialty Pharmacy, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 10
Published: Jan. 17, 2025
Both glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and continuous glucose monitoring (CGM) have been shown to improve glycated hemoglobin A1c (A1c) levels among patients with type 2 diabetes mellitus (T2DM). Recently, a US real-world study found statistically significant improvements in using GLP-1 RA CGM device, compared matched cohort receiving only RA. To assess the cost-effectiveness from payer perspective of initiating (FreeStyle Libre Systems) people living T2DM therapy, alone. A patient-level microsimulation model was run for 10,000 over lifetime horizon 3.0% discounting costs utilities. Patient characteristics were based on overall population subgroup not intensive insulin. The effect modeled as persistent reduction alone (overall = 0.37%; insulin 0.34%). Costs ($2,023) disutilities applied complications acute diabetic events. Outcomes assessed quality-adjusted life years (QALYs). base-case incremental ratio (incremental costs/incremental QALYs) plus vs $40,968/QALY (cost $484,180 $473,938; QALYs 13.37 13.12). Among insulin, $43,095/QALY. Scenario analysis showed that results robust changing assumptions. Probabilistic sensitivity had 64% probability being cost-effective at willingness-to-pay threshold $100,000 per QALY. From perspective, is when added therapies treatment T2DM, including
Language: Английский
Citations
0
Sensors and Actuators Reports, Journal Year: 2025, Volume and Issue: unknown, P. 100295 - 100295
Published: Feb. 1, 2025
Language: Английский
Citations
0
Advances in clinical chemistry, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Citations
0
Diabetes Technology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown
Published: March 18, 2025
Background: Devices for continuous glucose monitoring (CGM) have been developed to optimize blood control and liberate people with diabetes from finger-prick measurements. Since 2016, the devices reimbursed in Germany receiving insulin therapy, resulting their increased use among type 1 (T1D) 2 (T2D). We investigated prevalence of CGM its associated factors German adults 2017 2021/2022. Methods: Participants aged 18 years or older diagnosed were identified two nationwide population-based telephone surveys (n = 1396) 2021/2022 1456). Prevalence dynamics examined overall stratified by sociodemographic diabetes-related characteristics. Factors obtained logistic regression models. Results: The was 8.2% 16.6% An increase observed across all subgroups except those without antidiabetic medications. 31.1% 75.4% T1D, 6.3% 13.6% T2D, 14.6% 36.7% users. In both surveys, younger age, use, reporting hypoglycemia use. addition, 2017, higher education level absence obesity whereas 2021/2022, participation self-management program self-assessed quality care Conclusion: Among Germany, about twofold within 5 years, irrespective factors. Educational inequality diminished over time. self-rated recent provides further evidence support Germany.
Language: Английский
Citations
0
Microchemical Journal, Journal Year: 2025, Volume and Issue: unknown, P. 113795 - 113795
Published: April 1, 2025
Citations
0
Caderno Pedagógico, Journal Year: 2025, Volume and Issue: 22(7), P. e16351 - e16351
Published: May 16, 2025
Objetivo: Avaliar o uso da tecnologia no cuidado de pacientes com Diabetes Mellitus tipo 1. Métodos: Trata-se um estudo descritivo, baseado em revisão bibliográfica e análise documental sobre tecnologias DM1 histórico implementação tecnologias, relacionadas ao diabetes, âmbito distrital nacional. Resultados: Avanços tecnológicos longo dos anos revolucionaram tratamento do além diminuir fardo a doença, proporcionando maior autonomia qualidade vida. O Sistema Flash monitorização glicose realiza medição níveis líquido intersticial. A Secretaria Saúde Distrito Federal implementou Programa Monitorização Glicose contemplou DM1. Ademais, outros países, que dispõem serviço público saúde tais como Reino Unido, Canadá Austrália, também adotam critérios elegibilidade para financiamento dessa tecnologia. Conclusão: incorporação novas é grande desafio os gestores Sistemas Saúde. Espera-se que, por escaneamento intermitente seja incorporado SUS DM2, modo proporcionar acesso mais amplo à vivem garantindo princípio equidade, princípios fundamentais sistema brasileiro.
Citations
0
Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)
Published: April 5, 2024
Abstract Continuous glucose monitoring (CGM) is a promising, minimally invasive alternative to plasma measurements for calibrating physiology-based mathematical models of insulin-regulated metabolism, reducing the reliance on in-clinic measurements. However, use CGM glucose, particularly in combination with insulin measurements, develop personalized regulation remains unexplored. Here, we simultaneously measured interstitial concentrations using as well and during an oral tolerance test (OGTT) individuals overweight or obesity calibrate glucose-insulin dynamics. We compared model calibration, evaluated effects fit, identifiability, parameters’ association clinically relevant metabolic indicators. Models calibrated both resulted good parameter estimates associated indicators such sensitivity measures cases. Moreover, practical identifiability parameters was improved estimated glucose. Together these results suggest that may be considered calibration quantify dynamics regulation.
Language: Английский
Citations
3